🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Intraoperative Longitude-Latitude-Depth Localization Versus Preoperative CT-Guided Percutaneous Lung Puncture Localization for 0.8-2 cm Peripheral Pulmonary Nodules

RecruitingNAAges 18 Years - 80 YearsAllQilu Hospital of Shandong University
NCT07675889 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to learn whether intraoperative longitude-latitude-depth three-dimensional localization (LLD localization) is non-inferior to preoperative CT-guided percutaneous lung puncture localization for identifying 0.8-2 cm peripheral pulmonary nodules in adults undergoing video-assisted thoracoscopic surgery (VATS)-assisted sublobar resection. It will also evaluate the safety and perioperative effectiveness of the two localization methods. The main questions it aims to answer are: 1. Is the localization accuracy rate of LLD localization non-inferior to that of CT-guided percutaneous lung puncture localization? 2. Does LLD localization improve perioperative outcomes, including localization time, postoperative recovery, pain, quality of life, and perioperative complication rates? Researchers will compare LLD localization with CT-guided percutaneous lung puncture

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Clinically diagnosed pulmonary nodule by non-contrast chest CT. * Age 18 to 80 years. * Expected survival time of at least 12 months. * Single peripheral pulmonary nodule with a diameter between 0.8 cm and 2 cm. * Chest CT characteristics meeting both of the following criteria: 1. Solid component proportion ≤50%. 2. Located subpleurally or in the outer one-third of the lung parenchyma. * Willing to undergo VATS-assisted sublobar resection. * No contraindications to pulmonary localization procedures or surgery. * Able to understand the study and willing to sign written informed consent. Exclusion Criteria: * Use of other localization methods or other surgical procedures. * Concurrent participation in another clinical study. * Pregnancy. * Unwillingness or inability to cooperate with participation in this study for any reason.
💊

What it tests

  • Longitude-Latitude-Depth Localization
  • CT-Guided Percutaneous Lung Puncture Localization
📍

Where

4 sites
Xingyi People's Hospital
Xingyi, China
Ningxia Hui Autonomous Region People's Hospital
Yinchuan, China
Qilu Hospital of Shandong University
Jinan, China
Linqing People's Hospital
Linqing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy